Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. (Q38934630)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. |
scientific article |
Statements
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer (English)
Gilles Manceau
Emmanuel Buc
Thierry Lecomte
Philippe Rougier
Astrid Lievre
Bruno Landi
Michel Ducreux
Fréderic Bibeau
Olivier Bouché
Julia Reid
Steven Stone
Frédérique Penault-Llorca
2 November 2009